About BGNE

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

BGNE is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 247.9 M 2.47865E+08 234 234 0.32% 0.0031882 1.6 M 1617850
UBIO Proshares UltraPro Nasdaq Biotechnology 31.1 M 3.10775E+07 228 228 0.19% 0.00185256 181 K 181431
ADRA Invesco BLDRS Asia 50 ADR Index Fund 19.0 M 1.9E+07 50 50 0.36% 0.00358 68 K 67712
ADRE Invesco BLDRS Emerging Markets 50 ADR Index Fund 139.4 M 1.394E+08 50 50 0.42% 0.00415 579 K 578914
IBB iShares Nasdaq Biotechnology Index Fund 8.2 B 8.24908E+09 222 222 0.67% 0.0067 55.7 M 5.57164E+07
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,005 1005 0.03% 0.000340659 672 K 671750

Wait, Before You Leave...